NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued on Sunday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Down 0.2 %

NURO opened at $4.37 on Friday. The firm has a market cap of $8.91 million, a PE ratio of -0.95 and a beta of 2.18. The business has a fifty day simple moving average of $4.08 and a 200-day simple moving average of $3.95. NeuroMetrix has a fifty-two week low of $2.66 and a fifty-two week high of $4.73.

Institutional Trading of NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC bought a new stake in NeuroMetrix, Inc. (NASDAQ:NURO) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned approximately 0.57% of NeuroMetrix as of its most recent SEC filing. 19.40% of the stock is currently owned by institutional investors and hedge funds.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.